Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 02/07/24
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024PRNewsWire • 01/31/24
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of OnychomycosisPRNewsWire • 01/31/24
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024PRNewsWire • 01/30/24
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.PRNewsWire • 01/26/24
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and HepatologyPRNewsWire • 01/25/24
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SPRNewsWire • 01/23/24
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug AdministrationPRNewsWire • 01/19/24
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical PsychiatryPRNewsWire • 01/17/24
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved DrugsPRNewsWire • 01/12/24
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple SclerosisPRNewsWire • 12/07/23
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of GastroparesisPRNewsWire • 12/04/23
Vanda Pharmaceuticals Announces Participation at November 2023 Investor ConferencesPRNewsWire • 11/09/23
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023PRNewsWire • 11/01/23
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA LitigationPRNewsWire • 10/20/23
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro SummitPRNewsWire • 10/05/23